Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.
How this was made
The 30-second read
Why it matters
The EMA resubmission addresses previous GMP issues, clearing a regulatory hurdle and potentially expanding the drug's market to 35,000 SMA patients in Europe.
Market read
Regulatory progress for a rare‑disease therapy could drive SRRK stock and influence the broader rare‑disease biotech sector.
What to watch
The alternate fill‑finish facility's capacity and cost structure could affect margins post‑approval.
Background
Scholar Rock (NASDAQ: SRRK) recently received FDA approval for apitegromab (ISEMBYLD) in the U.S. and is now pursuing EU approval.
Ticker impact
Scholar Rock resubmitted its apitegromab Marketing Authorisation Application to the EMA, a new regulatory filing.
potential upside as investors price in a possible CHMP approval in H1 2027.
Regulatory clearance is a key catalyst for biotech valuations; the removal of the fill‑finish issue reduces risk.
Market effects
May boost confidence in other myostatin‑targeting programs and rare‑disease biotech pipelines.
European biotech sector could see modest uplift if approval is granted.
Limited to rare‑disease and neuromuscular therapy investors.
Counterpoint
Approval is not guaranteed; EMA may still raise concerns, making the stock vulnerable to a negative surprise.
Key entities
- CompanyScholar Rock
Biopharma developing apitegromab for SMA.
- RegulatorEuropean Medicines Agency (EMA)
Authority reviewing the MAA.
